Name
MAGNUM MEDICAL OÜ
Registry code
11332521
VAT number
EE101106531
Type
OÜ - Limited Liability Company
Status
Registered
Foundation date
22.12.2006 (17)
Financial year
01.05-30.04
Capital
2 556.00 €
Activity
46181 - Agents specialised in the sale of other particular products 46461 - Wholesale of medicines and other pharmacy goods
230 195 026 €
1 731 809 €
1%
-
20 846 373 €
28
Submitted
No tax arrears
8%
1%
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| Aktsiaselts MAGNUM 12371718 | 100% - 2 556.00 EUR | - | - | |
| Timo Danilov 27.10.1989 (34) | - | Board member | - | |
| Omanikukonto: MARGUS LINNAMÄE 05.01.1964 (60) | - | - | Indirect ownership | |
| Marika Pensa 14.08.1973 (50) | - | - | - | Board member |
| Veiko Vetto 13.06.1974 (49) | - | - | - | Board member |
| Mari Krass 06.05.1977 (47) | - | - | - | Chairman of the board |
| 2020 30.10.2021 | 2021 30.10.2022 | 2022 30.10.2023 | |
|---|---|---|---|
| Total Revenue | 194 004 634 € | 222 195 226 € | 230 195 026 € |
| Net profit (loss) for the period | -199 253 € | 241 455 € | 1 731 809 € |
| Profit Margin | -0% | 0% | 1% |
| Current Assets | 60 482 708 € | 68 374 726 € | 75 554 638 € |
| Fixed Assets | 18 385 724 € | 28 997 000 € | 44 263 000 € |
| Total Assets | 78 868 432 € | 97 371 726 € | 119 817 638 € |
| Current Liabilities | 59 995 323 € | 78 257 162 € | 95 971 265 € |
| Non Current Liabilities | - | - | 3 000 000 € |
| Total Liabilities | - | - | 98 971 265 € |
| Share Capital | - | - | - |
| Equity | 18 873 109 € | 19 114 564 € | 20 846 373 € |
| Employees | 27 | 26 | 28 |
| Turnover | State taxes | Labor taxes and payments | Employees | |
|---|---|---|---|---|
| 2023 Q4 | 162 897 283.9 € | 5 600 712.71 € | 149 492.13 € | 27 |
| 2023 Q3 | 157 636 240.3 € | 4 920 765.65 € | 141 039.4 € | 27 |
| 2023 Q2 | 158 645 287.5 € | 5 199 453.54 € | 126 232.36 € | 27 |
| 2023 Q1 | 165 923 033.8 € | 4 749 714.22 € | 122 333.4 € | 27 |
| 2022 Q4 | 158 872 628.2 € | 4 764 968.43 € | 128 180.37 € | 27 |
| 2022 Q3 | 137 691 725.3 € | 4 269 254.6 € | 112 357.1 € | 26 |
| 2022 Q2 | 151 891 402.1 € | 4 863 881.34 € | 105 725.99 € | 25 |
| 2022 Q1 | 157 351 324.8 € | 4 876 949.48 € | 105 486.47 € | 24 |
| 2021 Q4 | 163 842 762.4 € | 5 340 440.3 € | 112 819.8 € | 24 |
| 2021 Q3 | 148 949 831 € | 4 176 436.82 € | 110 710.85 € | 25 |
| 2021 Q2 | 148 397 207.1 € | 4 382 371.72 € | 98 566.64 € | 25 |
| 2021 Q1 | 139 810 514.7 € | 4 392 910.02 € | 91 780.5 € | 27 |
| 2020 Q4 | 132 964 688.44 € | 4 391 777.88 € | 95 293.47 € | 27 |
| 2020 Q3 | 112 719 265.12 € | 4 258 339.79 € | 84 986.21 € | 20 |
| 2020 Q2 | 136 190 846.9 € | 4 009 846.45 € | 101 532.99 € | 22 |
| 2020 Q1 | 122 519 768.09 € | 4 631 561.38 € | 89 106.31 € | 24 |
